Search results
8 maj 2024 · Abstract. The treatment for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) with immune checkpoint inhibitors (anti-PD1) with or without chemotherapy has led to an improvement in survival.
- Locally Advanced Head and Neck Cancer | American Society of Clinical ...
A discussion about induction chemotherapy (IC) cannot occur...
- Locally Advanced Head and Neck Cancer | American Society of Clinical ...
25 paź 2019 · Our objective was to evaluate the outcomes of metastatic head and neck squamous cell carcinoma (HNSCC) by disease burden with an emphasis on metastasis-directed therapy (MDT) in patients with...
The most common presenting symptoms of head and neck cancers include dysphagia, odynophagia, otalgia, hoarseness, mucosal irregularities and ulceration, oral or oropharyngeal pain, weight loss, or the presence of an unexplained neck mass.
16 maj 2013 · A discussion about induction chemotherapy (IC) cannot occur in the head and neck oncology community without triggering heated debate and controversy. Concurrent chemoradiotherapy (CRT) consisting of bolus cisplatin 100 mg/m 2 is a standard approach in locally advanced head and neck cancer (LAHNC).
12 cze 2019 · Key points. Current treatments for human papillomavirus-driven (HPV +) oropharyngeal squamous cell carcinoma (OPSCC), primarily derived from those for the more aggressive HPV − head and neck...
16 sty 2023 · Head and neck cancer (HNC) is malignant, genetically complex and difficult to treat and is the sixth most frequent cancer, with tobacco, alcohol and human papillomavirus being major risk...
10 gru 2022 · Simple Summary. Head and neck cancer (HNC) incidence has been steadily increasing since the 1990s. While the multimodal treatment approach for localized HNC is well established and renders a good treatment response, this is not the case for advanced or recurrent/metastatic HNC.
